Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

Learning from the 2012–2013 class of breakthrough therapies

Nature Reviews Drug Discovery volume 12, pages 891–893 (2013)Cite this article

Subjects

The expedited US regulatory pathway for 'breakthrough therapies' has already yielded its first two approvals and more than 26 designations, for 30 candidates in 22 indications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Breakthrough designations by therapeutic area and clinical stage.
Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mullard, A. Learning from the 2012–2013 class of breakthrough therapies. Nat Rev Drug Discov 12, 891–893 (2013). https://doi.org/10.1038/nrd4196

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4196

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research